ClinicalTrials.gg
CompletedNCT01888640FASTUpdated Oct 31, 2019Results posted

Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)

An interventional study of TENS in Fibromyalgia, sponsored by Kathleen Sluka. Completed at 2 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-31.

Sponsored by Kathleen Sluka · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
55th of 320
301 · median 72
Started
2013
with 12 others
No phase
167 of 369
34 open now
Registered
180th of 369
by date

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 55th largest by enrollment of the 320 interventional ones that give a count, is one of 13 that started in 2013, is one of 167 with no phase, and was the 180th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

Pain associated with fibromyalgia interferes with daily function, work, and social activities resulting in a decreased quality of life. People with fibromyalgia also have a significant amount of fatigue and a fear of movement. People with fibromyalgia show enhanced excitability of pain neurons in the central nervous system and reduced pain inhibition. Therefore, one of the main treatments for patients with fibromyalgia must focus on pain relief to allow the person to function more independently both at home and at work. Transcutaneous electrical nerve stimulation is used by health professionals to deliver electrical stimulation through the skin for pain control. Basic science studies, from the PI's laboratory show that TENS activates descending pain inhibitory pathways to inhibit excitability of pain neurons. Thus the ideal patient population for the treatment of TENS would be one in which there is enhanced central excitability and reduced inhibition; fibromyalgia is such a condition.

Hypothesis: The investigators hypothesize that application of Transcutaneous Electrical Nerve Stimulation (TENS) to patients with fibromyalgia will reduce resting and movement-related pain and reduce central excitability by restoring diffuse noxious inhibitory controls (DNIC), and that this decrease in pain and/or central excitability will reduce fatigue and fear of movement, thereby improving function and quality of life

Read the detailed description

This is a phase II randomized, double-blind, placebo controlled multi-center clinical trial involving a device, Transcutaneous Electrical Nerve Stimulation (TENS). TENS is a non-pharmacological agent which delivers electrical stimulation by a battery operated device via electrodes placed on the skin. TENS is considered to be a safe, inexpensive and non-invasive modality used to treat a variety of acute and chronic pain conditions. The initial phase of the study will randomly allocate subjects to receive active TENS, placebo TENS or standard care (No TENS). After participating in the 1 month random assignment, all subjects will receive active TENS for 1 month. The subjects will make 4 visits to the clinic approximately 2 to 3 1/2 hours each visit. Visits will entail questionnaires, functional tasks, accelerometry, TENS, pain and fatigue assessments.

Study Aims:

Aim #1: The primary aim of the study is to test the effectiveness of repeated TENS use on movement-related pain in people with fibromyalgia with random assignment to three treatments: standard care, placebo TENS and active Aim #2: A secondary aim will test if pain reduction by TENs results in a concomitant decrease in fatigue and fear of movement, and an increase in function and quality of life. Outcome measures will include physical function by directly assessing daily activity with an accelerometer, as well as performing specific functional tasks

03

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • TENS
  • Fibromyalgia
  • Accelerometer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants will be 18 to 70 years of age
  • Women may participate in the study, with the understanding that within the clinical population of fibromyalgia the there is a 7:1 ratio of female to male.
  • Diagnosis of Fibromyalgia by 1990 ACR criteria (11/18 tender points)
  • History of cervical or lumbar pain with fibromyalgia (this is expected in all patients since axial pain is required for diagnosis)
  • Current stable treatment regimen for the last 4 weeks and projected stable treatment regimen for the next 2 months.
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Current or history of cardiovascular, pulmonary, neurological, endocrine, or renal disease that would preclude the involvement in the study.
  • TENS use in the last 5 years
  • Pacemaker
  • Uncontrolled blood pressure or diabetes
  • Neuropathic pain condition
  • Systemic disorder (Lupus, PMR, RA, Psoriasis, Psoriatic arthritis)
  • Spinal fusion - cervical or lumbar
  • Metal implants in cervical or lumbar region
  • Severe skin allergy to adhesive
  • Allergy to nickel
  • Pain level less than 4
  • Pregnancy
  • Epilepsy
  • Change in or new drug or treatment program within the last month or in the next 2months, i.e. must have a stable treatment plan
  • Unstable medical or psychiatric condition which in the opinion of the investigator could compromise the subject's welfare or confound the study results
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
301 participants (actual)

Study arms

  • Active comparator
    ActiveTENS

    Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.

    Device: TENS

  • Placebo comparator
    Placebo TENS

    This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.

    Device: TENS

  • No intervention
    No TENS (Standard Care)

    Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.

Interventions

  • DeviceTENS

    TENS Parameters: Active TENS and Placebo TENS * TENS Frequency - 2-125 Hz * TENS Pulse Width - 200 µs * TENS Intensity - Maximal tolerable intensity * Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes. * Administration - Daily * TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region. Placebo TENS Unit Active TENS unit No TENS - Standard Care

    Also known as: Empi Select Unit

06

What researchers measure

Primary outcomes

  1. Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test

    Numeric rating scale of 0-10 (low to high scale) for pain with movement during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS

  2. Pain Rating With Movement (0-10 Low to High Scale) During Five Time Sit to Stand Test

    Numeric rating scale of 0-10 for pain with movement with five time sit to stand test. Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

Secondary outcomes

  1. Resting Pain (0-10 Low to High Scale)

    Numeric rating scale of 0-10 for resting pain; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Baseline, Visit 2 to Visit 3 (4 weeks, randomized to 3 groups) and Visit 4 (4 weeks, all groups home TENS)

  2. Fatigue Rating (0-10 Low to High Scale) During Six Minute Walk Test

    Fatigue measured with 0-10 numeric rating scale during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  3. Fatigue Rating (0-10 Low to High Scale) During Five Time Sit to Stand

    Fatigue measured by 0-10 numeric rating scale after five time sit to stand; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  4. Resting Fatigue Rating (0-10 Low to High Scale)

    Fatigue measured at rest with a 0-10 numeric rating scale; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  5. Fibromyalgia Impact Questionnaire Revised

    Disease Impact self report Questionnaire, Scoring 0-100; higher score indicates greater disease impact; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  6. Fibromyalgia Impact Questionnaire Revised - Pain Rating (0-10 Low to High Scale)

    numeric rating scale 0 to 10 from the Fibromyalgia Impact Questionnaire Revised: Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  7. Brief Pain Inventory - Interference (0-10 Low to High Scale)

    Brief Pain Inventory - Interference; Score 0-10 with higher score indicating greater interference; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  8. Brief Pain Inventory, Intensity (0-10 Low to High Scale)

    Brief Pain Inventory - Interference, Scale of 0-10 with higher score indicating greater intensity; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  9. Tampa Scale of Kinesiophobia (17 to 68 Low to High)

    Self report questionnaire with higher scores indicating greater kinesiophobia, score 17-68; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  10. Short Form Survey 36; Mental Component Score (T Score Mean of 50)

    Multidimensional Self Report Questionnaire, T-score; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Mental Health Component Score (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  11. Short Form Survey 36 Physical Component Score (T-score Mean of 50) Higher Scores Indicating Better Health

    Multidimensional self report scale, T score change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life .

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  12. Six Minute Walk Test

    6MWT - Feet walked as fast as comfortable in six minute; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  13. Five Time Sit to Stand Test Rate Per 10 Seconds

    Time for sit to stand for 5 repetitions converted to a rate of number of sit to stand per 10 seconds; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

  14. Moderate Vigorous Physical Activity Minutes Per Day

    Accelerometry data classification of physical activity in minutes per day, percent change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

    Time frame: Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)

07

Results

Posted Oct 31, 2019

Participant flow

Participant flow — Overall Study
MilestoneActive TENSPlacebo TENSNo TENS (Standard Care)
Started1039999
Completed766894
Not completed27315
Withdrew: Lost to follow-up120
Withdrew: Withdrawal by subject15114
Withdrew: Minimum dose not met10160
Withdrew: Given wrong unit (placebo)100
Withdrew: Excluded for prior tens010
Withdrew: Researcher termination of participant011

Outcome measures

PrimaryPain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test

Numeric rating scale of 0-10 (low to high scale) for pain with movement during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS
Reported as:
Mean · Units on a scale
Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test
Units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1.8 (-2.3 to -1.2)-0.8 (-1.4 to -0.2)0.00 (-0.5 to 0.6)
Change at 8 weeks-2.0 (-2.8 to -1.3)-1.9 (-2.7 to -1.2)-1.9 (-2.6 to -1.2)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.008 (To account for multiple tests involving pairwise treatment group comparisons, p-values were adjusted using Bonferroni's method) · Mean difference (final values): -1.0 · 95% CI -1.8 to -0.2
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = <0.0001 · Mean difference (final values): -1.8 · 95% CI -2.6 to -1.0
PrimaryPain Rating With Movement (0-10 Low to High Scale) During Five Time Sit to Stand Test

Numeric rating scale of 0-10 for pain with movement with five time sit to stand test. Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · units on a scale
Pain Rating With Movement (0-10 Low to High Scale) During Five Time Sit to Stand Test
units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1.6 (-2.30 to -1.0)-0.3 (-1.0 to 0.3)0.2 (-0.4 to 0.9)
Change at 8 weeks-1.9 (-2.6 to -1.1)-1.4 (-2.2 to -0.7)-1.3 (-2.1 to -0.6)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.002 · Mean difference (net): -1.3 · 95% CI -2.2 to -0.4
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = <0.0001 · Mean difference (final values): -1.8 · 95% CI -2.8 to -1.0
SecondaryResting Pain (0-10 Low to High Scale)

Numeric rating scale of 0-10 for resting pain; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Baseline, Visit 2 to Visit 3 (4 weeks, randomized to 3 groups) and Visit 4 (4 weeks, all groups home TENS)
Reported as:
Mean · units on a scale
Resting Pain (0-10 Low to High Scale)
units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1.9 (-2.5 to -1.4)-0.7 (-1.3 to -0.1)-0.5 (-1.1 to 0.00)
Change at 8 weeks-2.2 (-2.9 to -1.6)-1.9 (-2.6 to -1.2)-2.2 (-2.8 to -1.5)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.0006 · Mean difference (final values): -1.2 · 95% CI -2.1 to -0.4
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = <0.0001 · Mean difference (final values): -1.4 · 95% CI -2.2 to -0.6
SecondaryFatigue Rating (0-10 Low to High Scale) During Six Minute Walk Test

Fatigue measured with 0-10 numeric rating scale during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · Units on a scale
Fatigue Rating (0-10 Low to High Scale) During Six Minute Walk Test
Units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1.5 (-2.2 to -0.8)-0.1 (-0.9 to 0.7)0.4 (-0.3 to 1.1)
Change at 8 weeks-1.3 (-2.0 to -0.6)-0.9 (-1.7 to -0.2)-0.9 (-1.7 to -0.2)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.001 · Mean difference (final values): -1.4 · 95% CI -2.4 to -0.4
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = <0.0001 · Mean difference (final values): -1.9 · 95% CI -2.9 to -0.9
SecondaryFatigue Rating (0-10 Low to High Scale) During Five Time Sit to Stand

Fatigue measured by 0-10 numeric rating scale after five time sit to stand; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · Units on a scale
Fatigue Rating (0-10 Low to High Scale) During Five Time Sit to Stand
Units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1.2 (-1.9 to -0.5)-0.0 (-0.8 to 0.7)0.8 (0.1 to 1.5)
Change at 8 weeks-1.1 (-1.9 to -0.4)-0.8 (-1.6 to -0.1)-0.6 (-1.4 to 0.1)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.011 · Mean difference (final values): -1.2 · 95% CI -2.2 to -0.2
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = <0.0001 · Mean difference (final values): -2.0 · 95% CI -3.0 to -1.0
SecondaryResting Fatigue Rating (0-10 Low to High Scale)

Fatigue measured at rest with a 0-10 numeric rating scale; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · Units on a scale
Resting Fatigue Rating (0-10 Low to High Scale)
Units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1.9 (-2.6 to -1.2)-0.8 (-1.5 to -0.04)-0.4 (-1.0 to 0.4)
Change at 8 weeks-2.1 (-2.9 to -1.4)-1.6 (-2.4 to -0.8)-1.8 (-2.6 to -1.1)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.016 · Mean difference (final values): -1.2 · 95% CI -2.2 to -0.1
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = 0.0002 · Mean difference (final values): -1.57 · 95% CI -2.6 to -0.6
SecondaryFibromyalgia Impact Questionnaire Revised

Disease Impact self report Questionnaire, Scoring 0-100; higher score indicates greater disease impact; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · Units on a scale
Fibromyalgia Impact Questionnaire Revised
Units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-8.5 (-12.9 to 4.0)-3.4 (-6.5 to 0.3)-1.39 (-4.4 to 1.6)
Change at 8 weeks-9.6 (-13.8 to 5.4)-11.1 (-15.2 to 7.0)-10.7 (-14.8 to -6.6)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.074 · Mean difference (final values): -5.0 · 95% CI -10.4 to 0.3
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = 0.005 · Mean difference (final values): -7.1 · 95% CI -12.4 to -1.8
SecondaryFibromyalgia Impact Questionnaire Revised - Pain Rating (0-10 Low to High Scale)

numeric rating scale 0 to 10 from the Fibromyalgia Impact Questionnaire Revised: Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · units on a scale
Fibromyalgia Impact Questionnaire Revised - Pain Rating (0-10 Low to High Scale)
units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1.3 (-1.8 to -0.7)-0.4 (-0.9 to -0.2)-0.1 (-0.6 to 0.4)
Change at 8 weeks-1.4 (-2.0 to -0.8)-1.2 (-1.7 to -0.6)-1.4 (-1.9 to -0.8)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.018 · Mean difference (final values): -0.9 · 95% CI -1.7 to -0.1
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = 0.0006 · Mean difference (final values): -1.2 · 95% CI -1.9 to -0.4
SecondaryBrief Pain Inventory - Interference (0-10 Low to High Scale)

Brief Pain Inventory - Interference; Score 0-10 with higher score indicating greater interference; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · units on a scale
Brief Pain Inventory - Interference (0-10 Low to High Scale)
units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-0.9 (-1.4 to -0.5)-0.3 (-0.7 to 0.2)-0.3 (-0.7 to 0.2)
Change at 8 weeks-1.1 (-1.6 to -0.6)-0.9 (-1.4 to -0.3)-1.2 (-1.7 to -0.7)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.043 · Mean difference (final values): -0.7 · 95% CI -1.3 to -0.01
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = 0.048 · Mean difference (final values): -0.6 · 95% CI -1.3 to -0.0
SecondaryBrief Pain Inventory, Intensity (0-10 Low to High Scale)

Brief Pain Inventory - Interference, Scale of 0-10 with higher score indicating greater intensity; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · units on a scale
Brief Pain Inventory, Intensity (0-10 Low to High Scale)
units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-0.8 (-1.1 to -0.4)-0.3 (-0.6 to 0.1)0.15 (-0.2 to 0.5)
Change at 8 weeks-1.0 (-1.4 to -0.6)-0.9 (-1.3 to -0.5)-0.9 (-1.2 to -0.5)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.036 · Mean difference (final values): -0.5 · 95% CI -1.0 to -0.0
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = <0.0001 · Mean difference (final values): -0.9 · 95% CI -1.4 to -0.4
SecondaryTampa Scale of Kinesiophobia (17 to 68 Low to High)

Self report questionnaire with higher scores indicating greater kinesiophobia, score 17-68; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · units on a scale
Tampa Scale of Kinesiophobia (17 to 68 Low to High)
units on a scaleActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-0.7 (-2.0 to 0.6)-0.3 (-1.7 to 1.0)-0.2 (-1.4 to 1.1)
Change at 8 weeks-0.3 (-1.6 to 1.1)-2.3 (-3.7 to -0.9)-3.3 (-4.6 to -2.0)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = >0.99 · Mean difference (final values): -0.4 · 95% CI -2.3 to 1.5
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = >0.99 · Mean difference (final values): -0.6 · 95% CI -2.4 to 1.3
SecondaryShort Form Survey 36; Mental Component Score (T Score Mean of 50)

Multidimensional Self Report Questionnaire, T-score; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Mental Health Component Score (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · T-Score
Short Form Survey 36; Mental Component Score (T Score Mean of 50)
T-ScoreActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks2.3 (0.2 to 4.4)1.2 (-0.9 to 3.4)-0.04 (-2.1 to 2.0)
Change at 8 weeks2.1 (-0.2 to 4.4)3.6 (1.3 to 6.0)2.8 (0.6 to 5.0)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = >0.99 · Mean difference (final values): 1.1 · 95% CI -1.9 to 4.1
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = 0.17 · Mean difference (final values): 2.4 · 95% CI -0.6 to 5.3
SecondaryShort Form Survey 36 Physical Component Score (T-score Mean of 50) Higher Scores Indicating Better Health

Multidimensional self report scale, T score change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores" . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life .

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · T-Score
Short Form Survey 36 Physical Component Score (T-score Mean of 50) Higher Scores Indicating Better Health
T-ScoreActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks2.4 (1.0 to 3.7)1.2 (-0.2 to 2.5)1.4 (0.1 to 2.6)
Change at 8 weeks3.5 (2.0 to 5.1)3.2 (1.6 to 4.8)4.4 (2.9 to 5.9)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.36 · Mean difference (final values): 1.2 · 95% CI -0.7 to 3.1
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = 0.58 · Mean difference (final values): 1.0 · 95% CI -0.8 to 2.8
SecondarySix Minute Walk Test

6MWT - Feet walked as fast as comfortable in six minute; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · Feet
Six Minute Walk Test
FeetActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-1 (-55 to 54)-20 (-75 to 36)-42.1 (-95 to 11)
Change at 8 weeks15 (-42 to 71)16 (-41 to 74)-2 (-57 to 53)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = >0.99 · Mean difference (final values): 19 · 95% CI -58 to 96
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = >0.99 · Mean difference (final values): 42 · 95% CI -34 to 117
SecondaryFive Time Sit to Stand Test Rate Per 10 Seconds

Time for sit to stand for 5 repetitions converted to a rate of number of sit to stand per 10 seconds; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · sit-to-stand repetitions/10 seconds
Five Time Sit to Stand Test Rate Per 10 Seconds
sit-to-stand repetitions/10 secondsActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks0.6 (0.3 to 1.0)0.4 (0.0 to 0.7)0.1 (-0.3 to 0.4)
Change at 8 weeks0.6 (0.2 to 1.0)0.8 (0.4 to 1.3)0.6 (0.1 to 1.0)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = 0.96 · Mean difference (final values): 0.2 · 95% CI -0.2 to 0.7
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = 0.008 · Mean difference (final values): 0.6 · 95% CI 0.1 to 1.0
SecondaryModerate Vigorous Physical Activity Minutes Per Day

Accelerometry data classification of physical activity in minutes per day, percent change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups

Time frame:
Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)
Reported as:
Mean · Minutes per day
Moderate Vigorous Physical Activity Minutes Per Day
Minutes per dayActive TENSPlacebo TENSNo TENS (Standard Care)
Change at 4 weeks-9.4 (-27.8 to 13.5)2.5 (-18.6 to 29.1)-14.1 (-29.5 to 4.7)
Change at 8 weeks-6.8 (-27.2 to 19.3)-0.3 (-22.3 to 27.9)-17.0 (-33.9 to 4.1)
Statistical analysis
  • Active TENS vs Placebo TENS · Linear mixed models for repeated measure · p = >0.99
  • Active TENS vs No TENS (Standard Care) · Linear mixed models for repeated measure · p = >0.99

Adverse events

Collected over Visit 1 to Visit 4, 9 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active TENS0/103 (0%)0/103 (0%)12/103 (11.7%)
Placebo TENS0/99 (0%)1/99 (1%)10/99 (10.1%)
No TENS (Standard Care)0/99 (0%)2/99 (2%)15/99 (15.2%)
Pre-Randomization0/352 (0%)1/352 (0.3%)0/352 (0%)
Most frequent serious events
Most frequent serious events
EventActive TENSPlacebo TENSNo TENS (Standard Care)Pre-Randomization
Chest painCardiac disorders0/1031/990/990/352
Dehydration and gastrointestinal painGastrointestinal disorders0/1030/991/990/352
DepressionPsychiatric disorders0/1030/991/990/352
Chest painCardiac disorders0/1030/990/991/352
Most frequent other events
Showing 10 of 12
Most frequent other events
EventActive TENSPlacebo TENSNo TENS (Standard Care)Pre-Randomization
Pain with testingNervous system disorders12/10310/9915/990/352
Upper RespiratoryRespiratory, thoracic and mediastinal disorders7/1037/993/990/352
Upper Respiratory InfectionRespiratory, thoracic and mediastinal disorders7/1037/993/990/352
Skin Irritation with ElectrodesSkin and subcutaneous tissue disorders6/1032/990/990/352
Pain with TENS; At home, unspecifiedGeneral disorders4/1034/993/990/352
Common ColdRespiratory, thoracic and mediastinal disorders3/1034/992/990/352
FallGeneral disorders4/1033/992/990/352
Skin Irritation from actigraph bandSkin and subcutaneous tissue disorders2/1033/991/990/352
Headache or MigraineGeneral disorders3/1033/991/990/352
Dental ProceduresGeneral disorders2/1032/993/990/352

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Active TENSPlacebo TENSno TENS (Standard Care)Total
<=18 years0000
Between 18 and 65 years979395285
>=65 years66416
Age, Continuous
Age, Continuous(Years)Active TENSPlacebo TENSno TENS (Standard Care)Total
Mean44.7 ± 14.347.2 ± 12.648.6 ± 11.846.8 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Active TENSPlacebo TENSno TENS (Standard Care)Total
Female1039999301
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active TENSPlacebo TENSno TENS (Standard Care)Total
Hispanic or Latino55515
Not Hispanic or Latino969288276
Unknown or Not Reported22610
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active TENSPlacebo TENSno TENS (Standard Care)Total
American Indian or Alaska Native2103
Asian1214
Native Hawaiian or Other Pacific Islander5005
Black or African American0538
White908785262
More than one race43512
Unknown or Not Reported1157
Region of Enrollment
Region of Enrollment(participants)Active TENSPlacebo TENSno TENS (Standard Care)Total
United States1039999301
Pain with movement six minute walk test
Pain with movement six minute walk test(0 to 10 low to high scale)Active TENSPlacebo TENSno TENS (Standard Care)Total
Mean6.5 ± 1.96.2 ± 1.96.4 ± 1.96.4 ± 1.9
Pain with movement five time sit to stand
Pain with movement five time sit to stand(0 to 10 low to high scale)Active TENSPlacebo TENSno TENS (Standard Care)Total
Mean5.8 ± 2.45.5 ± 2.25.6 ± 2.25.6 ± 2.2

10 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Vanderbilt University
    Nashville, Tennessee 37262-2681, United States
09

References and documents

Publications

  • Sluka KA, Vance CG, Lisi TL. High-frequency, but not low-frequency, transcutaneous electrical nerve stimulation reduces aspartate and glutamate release in the spinal cord dorsal horn. J Neurochem. 2005 Dec;95(6):1794-801. doi: 10.1111/j.1471-4159.2005.03511.x. Epub 2005 Oct 17. PubMed 16236028 ↗
  • Rakel B, Cooper N, Adams HJ, Messer BR, Frey Law LA, Dannen DR, Miller CA, Polehna AC, Ruggle RC, Vance CG, Walsh DM, Sluka KA. A new transient sham TENS device allows for investigator blinding while delivering a true placebo treatment. J Pain. 2010 Mar;11(3):230-8. doi: 10.1016/j.jpain.2009.07.007. Epub 2009 Nov 27. PubMed 19945354 ↗
  • Liebano RE, Rakel B, Vance CGT, Walsh DM, Sluka KA. An investigation of the development of analgesic tolerance to TENS in humans. Pain. 2011 Feb;152(2):335-342. doi: 10.1016/j.pain.2010.10.040. Epub 2010 Dec 8. PubMed 21144659 ↗
  • Moran F, Leonard T, Hawthorne S, Hughes CM, McCrum-Gardner E, Johnson MI, Rakel BA, Sluka KA, Walsh DM. Hypoalgesia in response to transcutaneous electrical nerve stimulation (TENS) depends on stimulation intensity. J Pain. 2011 Aug;12(8):929-35. doi: 10.1016/j.jpain.2011.02.352. Epub 2011 Apr 9. PubMed 21481649 ↗
  • Pantaleao MA, Laurino MF, Gallego NL, Cabral CM, Rakel B, Vance C, Sluka KA, Walsh DM, Liebano RE. Adjusting pulse amplitude during transcutaneous electrical nerve stimulation (TENS) application produces greater hypoalgesia. J Pain. 2011 May;12(5):581-90. doi: 10.1016/j.jpain.2010.11.001. Epub 2011 Feb 1. PubMed 21277840 ↗
  • DeSantana JM, Walsh DM, Vance C, Rakel BA, Sluka KA. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. Curr Rheumatol Rep. 2008 Dec;10(6):492-9. doi: 10.1007/s11926-008-0080-z. PubMed 19007541 ↗
  • Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, Martin SA. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008 Oct;73(1):114-20. doi: 10.1016/j.pec.2008.06.005. Epub 2008 Jul 21. PubMed 18640807 ↗
  • Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct;36(10):2330-4. doi: 10.3899/jrheum.090368. PubMed 19820222 ↗
  • Walsh DM, Howe TE, Johnson MI, Sluka KA. Transcutaneous electrical nerve stimulation for acute pain. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006142. doi: 10.1002/14651858.CD006142.pub2. PubMed 19370629 ↗
  • Noehren B, Dailey DL, Rakel BA, Vance CG, Zimmerman MB, Crofford LJ, Sluka KA. Effect of transcutaneous electrical nerve stimulation on pain, function, and quality of life in fibromyalgia: a double-blind randomized clinical trial. Phys Ther. 2015 Jan;95(1):129-40. doi: 10.2522/ptj.20140218. Epub 2014 Sep 11. PubMed 25212518 ↗
  • Chimenti RL, Rakel BA, Dailey DL, Vance CGT, Zimmerman MB, Geasland KM, Williams JM, Crofford LJ, Sluka KA. Test-Retest Reliability and Responsiveness of PROMIS Sleep Short Forms Within an RCT in Women With Fibromyalgia. Front Pain Res (Lausanne). 2021 Jun 8;2:682072. doi: 10.3389/fpain.2021.682072. eCollection 2021. PubMed 35295526 ↗
  • Vance CGT, Zimmerman MB, Dailey DL, Rakel BA, Geasland KM, Chimenti RL, Williams JM, Golchha M, Crofford LJ, Sluka KA. Reduction in movement-evoked pain and fatigue during initial 30-minute transcutaneous electrical nerve stimulation treatment predicts transcutaneous electrical nerve stimulation responders in women with fibromyalgia. Pain. 2021 May 1;162(5):1545-1555. doi: 10.1097/j.pain.0000000000002144. PubMed 33230010 ↗
  • Merriwether EN, Agalave NM, Dailey DL, Rakel BA, Kolker SJ, Lenert ME, Spagnola WH, Lu Y, Geasland KM, Allen LH, Burton MD, Sluka KA. IL-5 mediates monocyte phenotype and pain outcomes in fibromyalgia. Pain. 2021 May 1;162(5):1468-1482. doi: 10.1097/j.pain.0000000000002089. PubMed 33003107 ↗
  • Dailey DL, Vance CGT, Rakel BA, Zimmerman MB, Embree J, Merriwether EN, Geasland KM, Chimenti R, Williams JM, Golchha M, Crofford LJ, Sluka KA. Transcutaneous Electrical Nerve Stimulation Reduces Movement-Evoked Pain and Fatigue: A Randomized, Controlled Trial. Arthritis Rheumatol. 2020 May;72(5):824-836. doi: 10.1002/art.41170. Epub 2020 Mar 18. PubMed 31738014 ↗
  • Merriwether EN, Frey-Law LA, Rakel BA, Zimmerman MB, Dailey DL, Vance CGT, Golchha M, Geasland KM, Chimenti R, Crofford LJ, Sluka KA. Physical activity is related to function and fatigue but not pain in women with fibromyalgia: baseline analyses from the Fibromyalgia Activity Study with TENS (FAST). Arthritis Res Ther. 2018 Aug 29;20(1):199. doi: 10.1186/s13075-018-1671-3. PubMed 30157911 ↗
  • Dailey DL, Frey Law LA, Vance CG, Rakel BA, Merriwether EN, Darghosian L, Golchha M, Geasland KM, Spitz R, Crofford LJ, Sluka KA. Perceived function and physical performance are associated with pain and fatigue in women with fibromyalgia. Arthritis Res Ther. 2016 Mar 16;18:68. doi: 10.1186/s13075-016-0954-9. PubMed 26979999 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — By publication

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be made available by publication by April 2019 and for one year after closeout of the study and upon request with a proposed study protocol for 5 years.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Apr 2018, 54 months.

Results were first posted in Oct 2019, 1 year 6 months after primary completion.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 54 months is above that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2013
First posted
Jun 28, 2013
StartActual
Sep 30, 2013
Primary completionActual
Apr 2, 2018
CompletionActual
Apr 2, 2018
Results first posted
Oct 31, 2019
Last update
Oct 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01888640
Lead sponsor
Kathleen Sluka
Responsible party
Kathleen Sluka (Professor, University of Iowa) — Sponsor-investigator
First posted
Jun 28, 2013
Start date
Sep 30, 2013
Primary completion
Apr 2, 2018
Completion
Apr 2, 2018
Results posted
Oct 31, 2019
Last update
Oct 31, 2019

Study contacts

Kathleen A Sluka, PhD, PT
principal investigator · University of Iowa
Leslie J. Crofford, MD
principal investigator · Vanderbilt University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion